COMPANY PROFILES

Founded in 2007, P-Cure is at the forefront of democratizing Proton Therapy, offering the most compact FDA-cleared solution for treating cancer patients. P-Cure's comprehensive system enables the planning and treatment of patients with Proton Therapy in both supine and seated positions, fitting linac-like vaults within existing/new radiation therapy centers.

Operating globally with production, service, and R&D platforms in the US, Israel, and China, P-Cure collaborates closely with healthcare providers supporting them in achieving unprecedented return on investment with operating breakeven typically within a year of implementation.

P-Cure is dedicated to ushering in a new era of life-saving technology accessible to all oncology centers and their patients, revolutionizing the cancer treatment landscape worldwide.

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence®. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data.

RaySearch's software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

Company profile to be published soon.

Gold Anchor is a fiducial marker for any soft tissue with proven clinical benefits. For proton therapy, Gold Anchor offers the following unique combination of benefits compared to alternatives:
  • Low dose perturbation due to the thin marker diameter.
  • Great kV-visibility compared to low density markers such as polymer or carbon markers.
  • Enhanced MR-visibility due to the unique and patented marker material, an alloy of gold and iron.
  • Industry-leading thin needle - 25G, 22G or 20G for Gold Anchor compared to 17G or 18G for most alternatives.
  • Anchoring marker design, allowing imaging for dose planning on the same day as implantation.

Orfit brings high precision and comfort to the positioning and immobilization of cancer patients in proton therapy thanks to devices that perfectly pair with advanced proton therapy delivery techniques. The Aerial® proton couch top optimizes the impact of the proton dose. Combined with Nanor® masks we bring more comfort to the patient while safeguarding stability and reproducibility.

RAD provides design-built modular facilities for the healthcare industry including radiotherapy vaults and clinics, proton vaults and clinics, and other specialty healthcare facilities. Our customized, factory fabricated solutions are completed up to 50% faster than standard construction and are installed for temporary, interim or permanent use. RAD’s Operating Leases require no capital, allowing projects to commence and complete sooner and customers to generate revenue faster.

Varian has long been on a mission to help create a world without fear of cancer. Now, as a Siemens Healthineers company, we are working as one, based on a more expansive perspective of the patient's journey than ever before. As a result, our vision for the future – and what we can achieve on behalf of patients – has expanded and become much more comprehensive.

Given the broad portfolio of imaging and cancer care technologies and services that we offer as one unified company, we are working together to create an oncology ecosystem that enables us to support care providers along the entire cancer care continuum.

Guiding Radiation Therapy

For more than 20 years, Vision RT has been on a mission to make radiation therapy more effective for cancer patients.

We are the inventors of, and market leaders in, Surface Guided Radiation Therapy (SGRT) which uses 3D cameras to help guide radiation therapy at every step: Simulation, Planning, Treatment and Dose Visualization.

Our systems are in active clinical use in more than 2,000 clinics globally, including all 15 of the USA’s 15 “Best Hospitals for Cancer”.

Cosylab is the leading provider of cutting-edge expertise, turnkey software solutions, and systems integration for innovative medical devices and cancer therapy systems. The company provides software products and services to the largest medical device manufacturers and cancer centres worldwide.

Cosylab is also a specialist in modular, medical-grade software functionalities for particle therapy (PT) devices, ranging from the accelerator control system, dose delivery, and safety system to the treatment control system, image guidance, and patient position verification. With over 20 years of experience solving complex challenges, Cosylab lowers the time to market or clinical commissioning, delivering solutions at a fixed cost and specified delivery date.

Company profile to be published soon.

Proton Collaborative Group (PCG) is committed to improving the outcomes of cancer patients by working collectively to advance the role of particle radiotherapy in cancer treatment. PCG serves as the link between state-of-the-art treatment centers, expert physicians, innovative and high-quality collaborative research, and the largest and most comprehensive proton therapy database in the world.

The SDX System is the only voluntary breath-hold device that pairs direct lung volume measurement with clear bio-visual feedback. It is the most precise way to achieve accurate, reproducible positioning for lung, liver, and other thoracoabdominal lesions.

The SDX System is currently being used in 18 Proton Therapy Centers in the US, including New York Proton Center, Penn Medicine, University of Maryland, and more proton therapy centers worldwide.

SDX system provides an automated beam delivery feature for Varian Probeam, IBA Proteus One, IBA Proteus Plus, Mevion S250i, and P-cure. SDX will also be compatible with the Leo Cancer Care equipment.

The mission of International Journal of Particle Therapy (the official journal of the Particle Therapy Co-Operative Group) is to provide a preferred venue for disseminating the most up-to-date information on the clinical, physical, and biological research in proton, light-ion, and heavy charged-particle therapy. Elsevier is the proud publishing partner of PTCOG as of January 1, 2024. Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance.

PTCOG-NA Copyright © 2019. All Rights Reserved.
Powered by APPTIDE | Terms of Service